Gastric cancer and colorectal cancer have something in common

Share This Post

Researchers at the Duke University Cancer Institute have found that H. pylori may lead to an increased risk of colorectal cancer, especially for people with color. People of color are more likely to be diagnosed and die of colorectal cancer.

The researchers further explored the link between H. pylori and colorectal cancerMore than half of the world’s population is infected with Helicobacter pylori, bacteria can cause gastric cancer and gastric ulcers. Researchers at Duke University collected samples from subjects of different races and checked antibody levels before cancer developed. Half of the more than 8,000 study participants continue to develop colorectal cancer. To determine whether the presence of antibodies increased the likelihood of developing colorectal cancer, the researchers compared the frequency of antibodies between cancer and non-cancer subjects. They observed similar rates of past infections in the two groups. As a result, a higher percentage of black and Latino subjects had H. pylori antibodies. This finding is consistent in both cancer and non-cancer tissues. Antibodies specific for Helicobacter pylori proteins are most commonly found in different ethnic groups. Most importantly, a high-level antibody to the H. pylori protein-VacA protein is closely related to the incidence of colorectal cancer in African-American and Asian Americans. 

The association between H. pylori and colorectal cancer plays a role in people of color and can significantly affect treatment options, action plans, and public health differences related to cancer. Medical professionals can identify high-risk people with colorectal cancer based on the status of Helicobacter pylori and reduce the incidence of cancer through treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy in Shanghai (2)
CAR T-Cell therapy

CAR T Cell Therapy in Shanghai, China: A Comprehensive Guide

CAR T Cell therapy is transforming cancer treatment, and Shanghai has become a global hub for this revolutionary procedure. With cutting-edge hospitals like Fudan University Shanghai Cancer Center and Ruijin Hospital, Shanghai offers advanced facilities, expert specialists, and competitive costs. Priced between $60,000 and $120,000, CAR T Cell therapy in Shanghai is more affordable than in Western countries, attracting international patients seeking world-class care and shorter treatment timelines.

CAR T Cell therapy in Mumbai, India
CAR T-Cell therapy

CAR T-Cell therapy in Mumbai, India

CAR T-cell therapy, an advanced cancer treatment, is now available in Mumbai, offering hope to those suffering from some types of blood cancers. This therapy modifies a patient’s T-cells to seek out and destroy cancer cells. It is being offered by many of the leading medical centers in Mumbai, enhancing survival rates and quality of life. With advanced technology and oncologists, Mumbai is slowly becoming a hub for CAR T-cell therapy in India.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy